乌拉地尔治疗非瓣膜性心力衰竭的疗效及安全性研究  

Efficacy and Safety of Urapidil for Treating Non- Valvular Heart Failure

作　　者：许圣云[1] 马小林[1] 方存明 

机构地区：[1]安徽省宣城市人民医院,安徽宣城242000

出　　处：《中国药业》2015年第16期73-74,共2页China Pharmaceuticals

摘　　要：目的探讨乌拉地尔治疗非瓣膜性心力衰竭的临床疗效及安全性。方法将110例患者随机分为治疗组与对照组,各55例。治疗组患者给予乌拉地尔治疗,对照组患者给予硝酸甘油治疗,均采用小剂量静脉注射泵的给药方式,治疗7 d。结果治疗组总有效率为90.91%,明显高于对照组的87.27%(P<0.05);两组患者的左心室射血分数(LVEF)、左心室舒张末期容积(LVEDF)均较治疗前提高(P<0.05),且治疗组的LVEDV提高更显著(P<0.05);两组患者的脑尿钠肽(BNP)、血浆内皮素-1(ET-1)水平均较治疗前显著改善(P<0.05),且治疗组改善更显著(P<0.05);治疗组头晕、恶心、心悸、出汗等不良反应的发生率为14.55%,显著低于对照组的36.36%(P<0.05)。结论小剂量持续静脉泵入乌拉地尔可有效改善非瓣膜性心力衰竭患者的临床症状及心肌功能,对神经-内分泌激素的异常改变有良好的抑制作用,且无严重不良反应,患者耐受性好、安全性高,值得临床推广。Objective To investigate tbe clinical efficacy and safety of Urapidil in treating non-valvular beart failure. Methods Totally 110 patients were randomly divided into treatment group and control group,55 cases in eacb group. Tbe treatment group was treated by Urapidil,and tbe control group was treated by Nitroglycerin. Tbe administration metbods for tbe two groups were small doses of intra-venous injection pump. Tbe two groups were treated for 7 d. Results Tbe total effective rate in tbe treatment group was 90. 91%, wbicb was significantly bigber tban 87. 27% in tbe control group（ P 〈 0. 05）;tbe LVEF and LVEDV in tbe two groups after treatment were significantly bigber tban before treatment（ P 〈 0. 05）,moreover tbe LVEDV in tbe treatment group increased more remarkably （ P 〈 0. 05）;tbe BPN and ET-1 in tbe two groups after treatment were significantly improved tban before treatment（ P 〈 0. 05）, moreover tbe improvement in tbe treatment group was more remarkable（ P 〈 0. 05）;Tbe adverse effects rate of dizziness,disgusting,pal-pitation,sweating in tbe treatment group was 14. 55%,wbicb was significantly lower tban 36. 36% in tbe control group（ P 〈 0. 05）. Conclusion Urapidil given by small doses of intravenous injection pump can improve tbe clinical symptoms and myocardial function of tbe patients witb non-valvular beart failure effectively,and bave good inbibitory effect on tbe nervous-endocrine bormone cbanges witbout serious adverse reaction,and it is bigbly safe,well tolerated and is wortby of clinical promotion.

关 键 词：乌拉地尔 非瓣膜性心力衰竭 临床疗效 安全性 

分 类 号：R969.4[医药卫生—药理学] R972.4[医药卫生—药学]